The gross margin decline from 81.8% to 79.5% year-over-year is modest, suggesting the combined product mix retains pricing power, but the operating margin collapse from 33.5% to 11.2% indicates that SG&A and integration expenses are absorbing the incremental revenue. Net margin fell to 4.5% from 29.1%, yet this appears driven by one-time charges rather than a structural deterioration in the core business. Investors should monitor whether operating leverage returns as integration synergies materialize, as the underlying ERT and Voxzogo franchises appear fundamentally profitable.

The decline in ROIC from 3.9% to 1.1% is largely attributable to the $5.1B Amicus outlay, which increased invested capital without an immediate earnings contribution. Historically, ROIC has been volatile, ranging from -0.6% to 3.9% over the past ten quarters, reflecting the lumpy nature of rare disease revenue and R&D spending. If management successfully integrates Amicus and accelerates GALAFOLD and POMBILITI, ROIC could recover, but the current level suggests the market is pricing in a multi-year turnaround. The low asset turnover of 0.10x indicates that the expanded asset base is not yet generating sufficient sales, a key metric to watch.

The CCC improvement from 697 to 596 days is misleading because DIO remains elevated at 686 days, far above the historical range of 418-894 days, suggesting that inventory levels for products like Roctavian may be building ahead of demand. DSO improved to 90 days from 88 days, while DPO rose to 180 days from 183 days, indicating stable payment terms with suppliers. The high DIO warrants scrutiny, as any product expiration could lead to write-downs, especially for high-cost gene therapies. Asset turnover remains low at 0.10x, reflecting the capital-intensive nature of biologics manufacturing and the recent acquisition.

The debt-to-equity increase from 0.23 to 0.66 reflects the $4.2B in total debt taken on to fund the Amicus acquisition, a strategic move that shifts the balance sheet from a net cash position to a leveraged one. Interest coverage of 1.97x is thin, down from 10.44x in the prior quarter, meaning operating income barely covers interest expense, which could constrain financial flexibility if earnings falter. D/EBITDA of 20.15x is elevated, but this is distorted by the low trailing EBITDA; as integration benefits accrue, this ratio should normalize. Investors should monitor covenant compliance and the company's ability to deleverage through free cash flow, which averaged 20.6% of revenue over the last four quarters.

The current ratio remains above 2.0, indicating adequate short-term liquidity, but the rapid decline from 5.81 to 2.39 highlights the cash drain from the acquisition. The quick ratio of 1.32 suggests that even without inventory, the company can cover current liabilities, though the reliance on inventory is higher than before. With $874M in cash and $4.2B in debt, the company's liquidity position is adequate but not robust; a severe operational shock could strain its ability to meet obligations. The $5.1B acquisition outflow in 2026Q2, per the cash flow statement, underscores the need for strong cash generation from the combined portfolio to rebuild the buffer.